Other Names(1R,2R)-N-[[[(1R,2R)-2-[[4,4-Difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl]oxy]cyclopentyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-[(1-methylcyclopropyl)sulfonyl]cyclopropanecarboxamide cyclic (12)-ether; A 1282576.0; ABT 493
CAS No1365970-03-1
GradeMedicine Grade
UsageGlecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly. It is being developed as a treatment of chronic hepatitis C infection in co-for
(1R,2R)-N-[[[(1R,2R)-2-[[4,4-Difluoro-4-(3-hydroxy-2-quinoxalinyl)-2-buten-1-yl]oxy]cyclopentyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-2-(difluoromethyl)-N-[(1-methylcyclopropyl)sulfonyl]cyclopropanecarboxamide cyclic (12)-ether; A 1282576.0; ABT 493
Medicine Grade
Other
C38H46F4N6O9S
Other
99%
Powder
838.87 Grams (g)
Glecaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly. It is being developed as a treatment of chronic hepatitis C infection in co-for
1365970-03-1
powder
Glecaprevir Chemical Trade Information
Shanghai
Letter of Credit (L/C) Western Union Letter of Credit at Sight (Sight L/C) Delivery Point (DP) Cash Against Delivery (CAD) Telegraphic Transfer (T/T) Days after Acceptance (DA)
1000 Ton Per Week
15 Days
Yes
Contact us for information regarding our sample policy
foil /plastic bag/ bottle
Australia South America Middle East Africa Central America Western Europe Asia Eastern Europe North America